Avastin Advisory Committee To Assess Validity Of Objective Response Rate Endpoint
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA questions whether imaging improvements in patients with glioblastoma metaforme are sufficient to denote clinical change.
You may also be interested in...
Avastin Clinical Benefit Trumps Anti-Tumor Effect In Glioblastoma, ODAC Says
Demonstration of an anti-tumor effect is not essential for a brain cancer indication if clinical benefit is provided, FDA's Oncology Drugs Advisory Committee indicated March 31 in recommending accelerated approval of Genentech's Avastin to treat relapsed glioblastoma multiforme
Avastin Clinical Benefit Trumps Anti-Tumor Effect In Glioblastoma, ODAC Says
Demonstration of an anti-tumor effect is not essential for a brain cancer indication if clinical benefit is provided, FDA's Oncology Drugs Advisory Committee indicated March 31 in recommending accelerated approval of Genentech's Avastin to treat relapsed glioblastoma multiforme
Avastin sBLA Clears Advisory Committee, Faces Quality of Life Hurdle
Accelerated approval for glioblastoma multiforme can be based on objective response rate, panel tells FDA.